[Study of L-dopa treatment and its principal side effects in aged subjects].
D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D001247:Asthenia / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002940:Circadian Rhythm / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy*; D011596:Psychomotor Disorders / Q000139:chemically induced; D013131:Spine / Q000187:drug effects; D014592:Uterine Hemorrhage / Q000139:chemically induced
D000928:Antidepressive Agents; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine
Etude du traitement à la L-dopa et de ses effets collatéraux principaux chez les sujets âgés.